Which combination represents empiric therapy for HAP/VAP with risk for Pseudomonas and MRSA?

Which combination represents empiric therapy for HAP/VAP with risk for Pseudomonas and MRSA?

• A. Piperacillin-tazobactam plus vancomycin
• B. Amoxicillin alone
• C. Ceftriaxone plus azithromycin
• D. Levofloxacin alone

Answer: (A)

Empiric therapy for HAP/VAP when there’s risk for Pseudomonas and MRSA requires two components: coverage for Pseudomonas and coverage for MRSA. Piperacillin-tazobactam provides strong anti-pseudomonal activity, addressing Pseudomonas and other Gram-negative bacteria common in hospital pneumonia. Vancomycin adds MRSA coverage, which is crucial when MRSA risk is present. Using both together ensures broad initial protection while cultures are pending, then therapy can be narrowed. The other options don’t meet both needs: amoxicillin alone lacks anti-pseudomonal activity; ceftriaxone plus azithromycin misses MRSA coverage and isn’t reliably anti-pseudomonal; levofloxacin alone doesn’t provide consistent MRSA coverage and is not ideal as monotherapy for HAP/VAP with MRSA risk.

Empiric therapy for HAP/VAP when there’s risk for Pseudomonas and MRSA requires two components: coverage for Pseudomonas and coverage for MRSA. Piperacillin-tazobactam provides strong anti-pseudomonal activity, addressing Pseudomonas and other Gram-negative bacteria common in hospital pneumonia. Vancomycin adds MRSA coverage, which is crucial when MRSA risk is present. Using both together ensures broad initial protection while cultures are pending, then therapy can be narrowed.

The other options don’t meet both needs: amoxicillin alone lacks anti-pseudomonal activity; ceftriaxone plus azithromycin misses MRSA coverage and isn’t reliably anti-pseudomonal; levofloxacin alone doesn’t provide consistent MRSA coverage and is not ideal as monotherapy for HAP/VAP with MRSA risk.